Skip to main content
Journal of Virology logoLink to Journal of Virology
. 1996 Sep;70(9):6418–6424. doi: 10.1128/jvi.70.9.6418-6424.1996

Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza.

B S Bender 1, C A Rowe 1, S F Taylor 1, L S Wyatt 1, B Moss 1, P A Small Jr 1
PMCID: PMC190672  PMID: 8709274

Abstract

Mice immunized with two intragastrically administered doses of a replication-deficient recombinant vaccinia virus containing the hemagglutinin and nucleoprotein genes from H1N1 influenza virus developed serum anti-H1 immunoglobulin G (IgG) antibody that completely protected the lungs from challenge with H1N1. Almost all of the mice given two intragastric doses also developed mucosal anti-H1 IgA antibody, and those with high anti-H1 IgA titers had completely protected noses. Intramuscular injection of the vaccine protected the lungs but not the noses from challenge. We also found that the vaccine enhanced recovery from infection caused by a shifted (H3N2) influenza virus, probably through the induction of nucleoprotein-specific cytotoxic T-lymphocyte activity. A replication-deficient, orally administered, enteric-coated, vaccinia virus-vectored vaccine might safely protect humans against influenza.

Full Text

The Full Text of this article is available as a PDF (245.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrew M. E., Coupar B. E. Efficacy of influenza haemagglutinin and nucleoprotein as protective antigens against influenza virus infection in mice. Scand J Immunol. 1988 Jul;28(1):81–85. doi: 10.1111/j.1365-3083.1988.tb02418.x. [DOI] [PubMed] [Google Scholar]
  2. Bender B. S., Bell W. E., Taylor S., Small P. A., Jr Class I major histocompatibility complex-restricted cytotoxic T lymphocytes are not necessary for heterotypic immunity to influenza. J Infect Dis. 1994 Nov;170(5):1195–1200. doi: 10.1093/infdis/170.5.1195. [DOI] [PubMed] [Google Scholar]
  3. Bender B. S., Croghan T., Zhang L., Small P. A., Jr Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med. 1992 Apr 1;175(4):1143–1145. doi: 10.1084/jem.175.4.1143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bender B. S., Johnson M. P., Small P. A. Influenza in senescent mice: impaired cytotoxic T-lymphocyte activity is correlated with prolonged infection. Immunology. 1991 Apr;72(4):514–519. [PMC free article] [PubMed] [Google Scholar]
  5. Bender B. S., Small P. A., Jr Heterotypic immune mice lose protection against influenza virus infection with senescence. J Infect Dis. 1993 Oct;168(4):873–880. doi: 10.1093/infdis/168.4.873. [DOI] [PubMed] [Google Scholar]
  6. Bender B. S., Taylor S. F., Zander D. S., Cottey R. Pulmonary immune response of young and aged mice after influenza challenge. J Lab Clin Med. 1995 Aug;126(2):169–177. [PubMed] [Google Scholar]
  7. Bennink J. R., Yewdell J. W., Smith G. L., Moller C., Moss B. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature. 1984 Oct 11;311(5986):578–579. doi: 10.1038/311578a0. [DOI] [PubMed] [Google Scholar]
  8. Bennink J. R., Yewdell J. W., Smith G. L., Moss B. Anti-influenza virus cytotoxic T lymphocytes recognize the three viral polymerases and a nonstructural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled. J Virol. 1987 Apr;61(4):1098–1102. doi: 10.1128/jvi.61.4.1098-1102.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Blancou J., Kieny M. P., Lathe R., Lecocq J. P., Pastoret P. P., Soulebot J. P., Desmettre P. Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature. 1986 Jul 24;322(6077):373–375. doi: 10.1038/322373a0. [DOI] [PubMed] [Google Scholar]
  10. Bloom B. R. Vaccines for the Third World. Nature. 1989 Nov 9;342(6246):115–120. doi: 10.1038/342115a0. [DOI] [PubMed] [Google Scholar]
  11. Brandtzaeg P. Overview of the mucosal immune system. Curr Top Microbiol Immunol. 1989;146:13–25. doi: 10.1007/978-3-642-74529-4_2. [DOI] [PubMed] [Google Scholar]
  12. CROSS R. M., KAPLAN C., MCCLEAN D. The heat resistance of dried smallpox vaccine. Lancet. 1957 Mar 2;272(6966):446–448. doi: 10.1016/s0140-6736(57)90521-4. [DOI] [PubMed] [Google Scholar]
  13. Cadoz M., Strady A., Meignier B., Taylor J., Tartaglia J., Paoletti E., Plotkin S. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet. 1992 Jun 13;339(8807):1429–1432. doi: 10.1016/0140-6736(92)92027-d. [DOI] [PubMed] [Google Scholar]
  14. Clements M. L., Betts R. F., Tierney E. L., Murphy B. R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol. 1986 Jul;24(1):157–160. doi: 10.1128/jcm.24.1.157-160.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Eichelberger M., Allan W., Zijlstra M., Jaenisch R., Doherty P. C. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med. 1991 Oct 1;174(4):875–880. doi: 10.1084/jem.174.4.875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Frank A. L., Taber L. H., Wells J. M. Individuals infected with two subtypes of influenza A virus in the same season. J Infect Dis. 1983 Jan;147(1):120–124. doi: 10.1093/infdis/147.1.120. [DOI] [PubMed] [Google Scholar]
  17. Gammelin M., Mandler J., Scholtissek C. Two subtypes of nucleoproteins (NP) of influenza A viruses. Virology. 1989 May;170(1):71–80. doi: 10.1016/0042-6822(89)90353-x. [DOI] [PubMed] [Google Scholar]
  18. Ghendon Y. The immune response of humans to live and inactivated influenza vaccines. Adv Exp Med Biol. 1989;257:37–45. doi: 10.1007/978-1-4684-5712-4_6. [DOI] [PubMed] [Google Scholar]
  19. Gorman O. T., Bean W. J., Kawaoka Y., Donatelli I., Guo Y. J., Webster R. G. Evolution of influenza A virus nucleoprotein genes: implications for the origins of H1N1 human and classical swine viruses. J Virol. 1991 Jul;65(7):3704–3714. doi: 10.1128/jvi.65.7.3704-3714.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hochstein-Mintzel V., Huber H. C., Stickl H. Die orale und nasale Immunisierung mit Poxvirus vacciniae. 3. Tierexperimentelle Untersuchungen. Zentralbl Bakteriol Orig B. 1972 Aug;156(1):30–96. [PubMed] [Google Scholar]
  21. Kanesaki T., Murphy B. R., Collins P. L., Ogra P. L. Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus. J Virol. 1991 Feb;65(2):657–663. doi: 10.1128/jvi.65.2.657-663.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lawson C. M., Bennink J. R., Restifo N. P., Yewdell J. W., Murphy B. R. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J Virol. 1994 Jun;68(6):3505–3511. doi: 10.1128/jvi.68.6.3505-3511.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Liang S., Mozdzanowska K., Palladino G., Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol. 1994 Feb 15;152(4):1653–1661. [PubMed] [Google Scholar]
  24. Lin Y. L., Askonas B. A. Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions. J Exp Med. 1981 Aug 1;154(2):225–234. doi: 10.1084/jem.154.2.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lukacher A. E., Braciale V. L., Braciale T. J. In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med. 1984 Sep 1;160(3):814–826. doi: 10.1084/jem.160.3.814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mayr A., Danner K. Bedeutung von Tierpocken für den Menschen nach Aufhebung der Pflichtimpfung gegen Pocken. Berl Munch Tierarztl Wochenschr. 1979 Jul 1;92(13):251–256. [PubMed] [Google Scholar]
  27. Mayr A., Stickl H., Müller H. K., Danner K., Singer H. Der Pockenimpfstamm MVA: Marker, genetische Struktur, Erfahrungen mit der parenteralen Schutzimpfung und Verhalten im abwehrgeschwächten Organismus. Zentralbl Bakteriol B. 1978 Dec;167(5-6):375–390. [PubMed] [Google Scholar]
  28. Mazanec M. B., Coudret C. L., Fletcher D. R. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol. 1995 Feb;69(2):1339–1343. doi: 10.1128/jvi.69.2.1339-1343.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Mazanec M. B., Kaetzel C. S., Lamm M. E., Fletcher D., Nedrud J. G. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6901–6905. doi: 10.1073/pnas.89.15.6901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. McGhee J. R., Mestecky J., Dertzbaugh M. T., Eldridge J. H., Hirasawa M., Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine. 1992;10(2):75–88. doi: 10.1016/0264-410x(92)90021-b. [DOI] [PubMed] [Google Scholar]
  31. McGhee J. R., Mestecky J. In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens. Infect Dis Clin North Am. 1990 Jun;4(2):315–341. [PubMed] [Google Scholar]
  32. Meitin C. A., Bender B. S., Small P. A., Jr Enteric immunization of mice against influenza with recombinant vaccinia. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11187–11191. doi: 10.1073/pnas.91.23.11187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Meitin C. A., Bender B. S., Small P. A., Jr Influenza immunization: intranasal live vaccinia recombinant contrasted with parenteral inactivated vaccine. Vaccine. 1991 Oct;9(10):751–756. doi: 10.1016/0264-410x(91)90292-e. [DOI] [PubMed] [Google Scholar]
  34. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol. 1991 May;72(Pt 5):1031–1038. doi: 10.1099/0022-1317-72-5-1031. [DOI] [PubMed] [Google Scholar]
  35. Moss B. Vaccinia virus: a tool for research and vaccine development. Science. 1991 Jun 21;252(5013):1662–1667. doi: 10.1126/science.2047875. [DOI] [PubMed] [Google Scholar]
  36. Nuchtern J. G., Bonifacino J. S., Biddison W. E., Klausner R. D. Brefeldin A implicates egress from endoplasmic reticulum in class I restricted antigen presentation. Nature. 1989 May 18;339(6221):223–226. doi: 10.1038/339223a0. [DOI] [PubMed] [Google Scholar]
  37. Palladino G., Mozdzanowska K., Washko G., Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol. 1995 Apr;69(4):2075–2081. doi: 10.1128/jvi.69.4.2075-2081.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Paoletti E., Lipinskas B. R., Samsonoff C., Mercer S., Panicali D. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A. 1984 Jan;81(1):193–197. doi: 10.1073/pnas.81.1.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Renegar K. B., Small P. A., Jr Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J Virol. 1991 Apr;65(4):2146–2148. doi: 10.1128/jvi.65.4.2146-2148.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Renegar K. B., Small P. A., Jr Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol. 1991 Mar 15;146(6):1972–1978. [PubMed] [Google Scholar]
  41. Robbins A., Freeman P. Obstacles to developing vaccines for the Third World. Sci Am. 1988 Nov;259(5):126–133. doi: 10.1038/scientificamerican1188-126. [DOI] [PubMed] [Google Scholar]
  42. Rupprecht C. E., Wiktor T. J., Johnston D. H., Hamir A. N., Dietzschold B., Wunner W. H., Glickman L. T., Koprowski H. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc Natl Acad Sci U S A. 1986 Oct;83(20):7947–7950. doi: 10.1073/pnas.83.20.7947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. SCHULMAN J. L., KILBOURNE E. D. INDUCTION OF PARTIAL SPECIFIC HETEROTYPIC IMMUNITY IN MICE BY A SINGLE INFECTION WITH INFLUENZA A VIRUS. J Bacteriol. 1965 Jan;89:170–174. doi: 10.1128/jb.89.1.170-174.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Scherle P. A., Palladino G., Gerhard W. Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells. J Immunol. 1992 Jan 1;148(1):212–217. [PubMed] [Google Scholar]
  45. Small P. A., Jr Influenza: pathogenesis and host defense. Hosp Pract (Off Ed) 1990 Nov 15;25(11):51-4, 57-62. doi: 10.1080/21548331.1990.11704033. [DOI] [PubMed] [Google Scholar]
  46. Smith G. L., Murphy B. R., Moss B. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A. 1983 Dec;80(23):7155–7159. doi: 10.1073/pnas.80.23.7155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Sonoguchi T., Naito H., Hara M., Takeuchi Y., Fukumi H. Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. J Infect Dis. 1985 Jan;151(1):81–88. doi: 10.1093/infdis/151.1.81. [DOI] [PubMed] [Google Scholar]
  48. Steinhoff M. C., Fries L. F., Karron R. A., Clements M. L., Murphy B. R. Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children. J Clin Microbiol. 1993 Apr;31(4):836–838. doi: 10.1128/jcm.31.4.836-838.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H. C., Schäfer H., Holzner A. MVA-Stufenimpfung gegen Pocken. Klinische Erprobung des attenuierten Pocken-Lebendimpfstoffes, Stamm MVA. Dtsch Med Wochenschr. 1974 Nov 22;99(47):2386–2392. doi: 10.1055/s-0028-1108143. [DOI] [PubMed] [Google Scholar]
  50. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847–10851. doi: 10.1073/pnas.89.22.10847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Sutter G., Wyatt L. S., Foley P. L., Bennink J. R., Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine. 1994 Aug;12(11):1032–1040. doi: 10.1016/0264-410x(94)90341-7. [DOI] [PubMed] [Google Scholar]
  52. Townsend A. R., McMichael A. J., Carter N. P., Huddleston J. A., Brownlee G. G. Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells. Cell. 1984 Nov;39(1):13–25. doi: 10.1016/0092-8674(84)90187-9. [DOI] [PubMed] [Google Scholar]
  53. Townsend A., Ohlén C., Bastin J., Ljunggren H. G., Foster L., Kärre K. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature. 1989 Aug 10;340(6233):443–448. doi: 10.1038/340443a0. [DOI] [PubMed] [Google Scholar]
  54. Wells M. A., Ennis F. A., Albrecht P. Recovery from a viral respiratory infection. II. Passive transfer of immune spleen cells to mice with influenza pneumonia. J Immunol. 1981 Mar;126(3):1042–1046. [PubMed] [Google Scholar]
  55. Werner G. T., Jentzsch U., Metzger E., Simon J. Studies on poxvirus infections in irradiated animals. Arch Virol. 1980;64(3):247–256. doi: 10.1007/BF01322704. [DOI] [PubMed] [Google Scholar]
  56. Yap K. L., Ada G. L., McKenzie I. F. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature. 1978 May 18;273(5659):238–239. doi: 10.1038/273238a0. [DOI] [PubMed] [Google Scholar]
  57. Yetter R. A., Lehrer S., Ramphal R., Small P. A., Jr Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect Immun. 1980 Aug;29(2):654–662. doi: 10.1128/iai.29.2.654-662.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Yewdell J. W., Bennink J. R., Hosaka Y. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science. 1988 Feb 5;239(4840):637–640. doi: 10.1126/science.3257585. [DOI] [PubMed] [Google Scholar]
  59. Yewdell J. W., Bennink J. R., Smith G. L., Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1985 Mar;82(6):1785–1789. doi: 10.1073/pnas.82.6.1785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Yilma T., Hsu D., Jones L., Owens S., Grubman M., Mebus C., Yamanaka M., Dale B. Protection of cattle against rinderpest with vaccinia virus recombinants expressing the HA or F gene. Science. 1988 Nov 18;242(4881):1058–1061. doi: 10.1126/science.3194758. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES